Quantum BioPharma Outlined Lucid-MS Phase 2 Progress
The firm detailed plans for its multiple sclerosis drug and the IPO trajectory of its subsidiary, unbuzzd.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you believe pharmaceutical companies are successfully developing better treatments for chronic conditions?
Quantum BioPharma has advanced its multiple sclerosis treatment, Lucid-MS, into Phase 2 clinical trials. The company also detailed the ongoing IPO process for unbuzzd, a firm in which Quantum holds a 20% equity stake.
Why it matters
The progress of Lucid-MS marks a shift in clinical development for regenerative myelin treatments, while the unbuzzd IPO highlights the complex equity structures defining the biotech startup landscape.
Quantum BioPharma retains a 7% royalty stream on unbuzzd sales up to a $250 million threshold, after which the rate adjusts to 3%. The firm currently maintains a 19.48% ownership stake in unbuzzd as of June 30, 2026.
The players
Quantum BioPharma Ltd.
A biotechnology company focused on the development of regenerative therapies for multiple sclerosis and equity management in subsidiary ventures.
Anthony Durkacz
A key executive at Quantum BioPharma who oversees the clinical progression of the Lucid-MS pipeline and corporate financial strategy.
IBN
An Austin-based media and investor network providing syndication channels for over 500 companies in the healthcare and technology sectors.
unbuzzd
A biotechnology entity currently navigating an IPO process to fund a broad-market launch of its clinical assets.
The details
Lucid-MS is a pharmaceutical candidate engineered to target myelin, the protective sheath surrounding nerve fibers, to prevent or reverse its degradation. The development strategy involves a transition into Phase 2 trials to evaluate efficacy in human subjects. Concurrently, unbuzzd is preparing for a full marketing launch contingent on the successful completion of its current IPO process.
Timeline
March 2026: Peer-reviewed study on unbuzzd was published.
June 30, 2026: Quantum BioPharma recorded a 19.48% ownership of unbuzzd.
September 30, 2026: IBN released the new podcast episode featuring Anthony Durkacz.
The Tech Race
This development follows the established trajectory of the Lucid-MS Phase 2 clinical trial as it moves toward human efficacy validation. It places Quantum BioPharma among a small group of firms attempting to bridge the gap between myelin research and commercialized therapeutic products.
Investors and stakeholders should monitor the unbuzzd IPO filing for updates on the marketing launch timeline. The availability of Lucid-MS remains contingent on the successful completion of Phase 2 trial benchmarks.
The takeaway
The firm continues to balance aggressive capital raising via the unbuzzd IPO with the high-stakes clinical validation of Lucid-MS. Market observers should watch for the official IPO registration documents as the next indicator of company solvency and growth.
Further reading
For more context on the local industry, visit Biotech.
More information
Listen to the complete episode and view additional disclosures on the BioMedWire podcast.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical companies are successfully developing better treatments for chronic conditions?
